Indeed, autologous and/or allogeneic GM-CSF-secreting tumor cell vaccines have demonstrated evidence of clinical and/or in vitro immunologic responses in patients with various types of cancer [18–22]. The gene discussed is CSF2; the disease is neoplasm.